Page 288 - Read Online

Gonzales N, Lai E, Massman P. Chronic donepezil treatment is disease: an observational post‑marketing study. J Neural Transm
associated with slowed cognitive decline in Alzheimer’s disease. 2011;118:1255‑9.
Dement Geriatr Cogn Disord 2001;12:295‑300. 77. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on
72. Areosa SA, Sherriff F, McShane R. Memantine for dementia. behavioural symptoms in Alzheimer’s disease patients: an analysis
Cochrane Database Syst Rev 2005;20:CD003154. of the Neuropsychiatric Inventory (NPI) data of two randomised,
73. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, controlled studies. Int J Geriatr Psychiatry 2005;20:459‑64.
Perdomo CA, Richardson S. Donepezil preserves cognition and 78. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E,
global function in patients with severe Alzheimer disease. Neurology Donepezil MSIG. A 24‑week, randomized, double‑blind study of
2007;69:459‑69. donepezil in moderate to severe Alzheimer’s disease. Neurology
74. Farlow M, Veloso F, Moline M, Yardley J, Brand‑Schieber E, 2001;57:613‑20.
Bibbiani F, Zou H, Hsu T, Satlin A. Safety and tolerability of 79. Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease.
donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Drugs Aging 2011;28:539‑46.
Neurol 2011;11:57. 80. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R,
75. Schulz JB, Rainer M, Klunemann HH, Kurz A, Wolf S, Sternberg K, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R,
Tennigkeit F. Sustained effects of once‑daily memantine treatment Jones R, Jones R, McKeith I, Macharouthu A, O’Brien J, Passmore P,
on cognition and functional communication skills in patients with Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C,
moderate to severe Alzheimer’s disease: results of a 16‑week Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R,
open‑label trial. J Alzheimers Dis 2011;25:463‑75. Johnson T, Bentham P, Phillips P. Donepezil and memantine
76. Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, for moderate‑to‑severe Alzheimer’s disease. N Engl J Med
Mucke HA. Memantine in moderate to severe Alzheimer’s 2012;366:893‑903.

280 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015 PB